Phong Phu Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Phong Phu Pharmaceutical has been growing earnings at an average annual rate of 18.9%, while the Pharmaceuticals industry saw earnings growing at 11.9% annually. Revenues have been growing at an average rate of 3.1% per year. Phong Phu Pharmaceutical's return on equity is 13.6%, and it has net margins of 12.3%.
Key information
18.9%
Earnings growth rate
14.6%
EPS growth rate
Pharmaceuticals Industry Growth | 13.0% |
Revenue growth rate | 3.1% |
Return on equity | 13.6% |
Net Margin | 12.3% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Phong Phu Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 145,985 | 17,983 | 26,601 | 0 |
31 Dec 23 | 152,172 | 20,120 | 26,037 | 0 |
30 Sep 23 | 154,100 | 19,527 | 26,619 | 0 |
30 Jun 23 | 156,028 | 18,934 | 27,200 | 0 |
31 Mar 23 | 150,172 | 18,764 | 26,519 | 0 |
31 Dec 22 | 150,575 | 20,611 | 26,096 | 0 |
30 Sep 22 | 148,075 | 21,583 | 25,899 | 0 |
30 Jun 22 | 145,576 | 22,555 | 25,702 | 0 |
31 Mar 22 | 144,073 | 21,310 | 25,209 | 0 |
31 Dec 21 | 133,289 | 16,893 | 25,543 | 0 |
30 Sep 21 | 127,932 | 13,546 | 24,878 | 0 |
30 Jun 21 | 117,879 | 10,446 | 22,939 | 0 |
31 Mar 21 | 113,224 | 10,046 | 22,907 | 0 |
31 Dec 20 | 116,257 | 9,815 | 23,330 | 0 |
30 Sep 20 | 125,308 | 11,538 | 23,697 | 0 |
30 Jun 20 | 137,335 | 13,553 | 23,970 | 0 |
31 Mar 20 | 150,610 | 12,875 | 23,664 | 0 |
31 Dec 19 | 151,529 | 12,212 | 21,966 | 0 |
30 Sep 19 | 144,577 | 10,489 | 19,430 | 0 |
30 Jun 19 | 134,302 | 6,713 | 18,128 | 0 |
31 Mar 19 | 122,108 | 5,230 | 16,584 | 0 |
31 Dec 18 | 125,392 | 6,554 | 16,091 | 0 |
30 Sep 18 | 124,716 | 5,684 | 16,513 | 0 |
30 Jun 18 | 126,341 | 6,489 | 16,715 | 0 |
31 Mar 18 | 131,009 | 7,908 | 16,875 | 0 |
31 Dec 17 | 131,915 | 6,344 | 17,015 | 0 |
30 Sep 17 | 131,825 | 6,310 | 16,519 | 0 |
30 Jun 17 | 132,096 | 6,625 | 15,417 | 0 |
31 Mar 17 | 125,940 | 6,721 | 14,554 | 0 |
31 Dec 16 | 120,904 | 7,536 | 13,257 | 0 |
30 Sep 16 | 116,098 | 6,122 | 11,955 | 0 |
30 Jun 16 | 106,706 | 4,361 | 12,209 | 0 |
31 Mar 16 | 104,192 | 5,666 | 11,912 | 0 |
31 Dec 15 | 99,314 | 4,812 | 11,788 | 0 |
30 Sep 15 | 93,511 | 9,406 | 11,823 | 0 |
30 Jun 15 | 90,706 | 8,925 | 10,371 | 0 |
31 Mar 15 | 105,511 | 5,451 | 11,476 | 0 |
31 Dec 14 | 107,807 | 5,944 | 11,964 | 0 |
30 Sep 14 | 112,383 | -1,229 | 12,948 | 0 |
30 Jun 14 | 120,259 | -2,638 | 13,039 | 0 |
31 Mar 14 | 104,139 | -5,151 | 11,432 | 0 |
01 Jan 14 | 101,035 | -5,072 | 10,123 | 0 |
30 Sep 13 | 98,789 | -2,350 | 8,309 | 0 |
30 Jun 13 | 93,330 | -215 | 7,905 | 0 |
Quality Earnings: PPP has high quality earnings.
Growing Profit Margin: PPP's current net profit margins (12.3%) are lower than last year (12.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PPP's earnings have grown by 18.9% per year over the past 5 years.
Accelerating Growth: PPP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PPP had negative earnings growth (-4.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-5.5%).
Return on Equity
High ROE: PPP's Return on Equity (13.6%) is considered low.